Low-dose paclitaxel modulates tumour fibrosis in gastric cancer

International Journal of Oncology

Volumn 42, Issue 4, 2013, Pages 1167-1174

  Tsukada, Tomoya ^a   Fushida, Sachio ^a   Harada, Shinichi ^a   Terai, Shiroh ^a   Yagi, Yasumichi ^a   Kinoshita, Jun ^a   Oyama, Katsunobu ^a   Tajima, Hidehiro ^a   Ninomiya, Itasu ^a   Fujimura, Takashi ^a   Ohta, Tetsuo ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Epithelial mesenchymal transitions; Fibrosis; Gastric cancer; Human peritoneal mesothelial cell; Paclitaxel

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALPHA SMOOTH MUSCLE ACTIN; CISPLATIN; COLLAGEN TYPE 1; FLUOROURACIL; PACLITAXEL; SMAD PROTEIN; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CELL STRUCTURE; CELL VIABILITY; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CYTOSTASIS; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; PERITONEUM CELL; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STOMACH CANCER; WESTERN BLOTTING;

ACTINS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CADHERINS; CELL LINE, TUMOR; CELL SHAPE; CISPLATIN; COLLAGEN TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL-MESENCHYMAL TRANSITION; FIBROSIS; FLUOROURACIL; GENE EXPRESSION; HUMANS; PACLITAXEL; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SMAD2 PROTEIN; STOMACH NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84874583350     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1801     Document Type: Article

References (48)

1. Fushida S, Kinoshita J, Yagi Y, Funaki H, Kinami S, Ninomiya I, Fujimura T, Nishimura G, Kayahara M and Ohta T: Dual anti-cancer effects of weekly intraperitoneal docetaxel in treatment of advanced gastric cancer patients with peritoneal carcinomatosis: a feasibility and pharmacokinetic study. Oncol Rep 19:1305-1310, 2008.
2. Shimada S, Tanaka E, Marutsuka T, Honmyo U, Tokunaga H, Yagi Y, Aoki N and Ogawa M: Extensive intraoperative peritoneal lavage and chemotherapy for gastric cancer patients with peritoneal free cancer cells. Gastric Cancer 5:168-172, 2002.
3. Yonemura Y, Kawamura T, Nojima N, Bandou E, Keizou T, Fujita H, Michiwa Y, Fujimura T, Fushida S, Ajisaka H and Miwa K: Postoperative results of left upper abdominal evisceration for advanced gastric cancer. Hepatogastroenterology 47:571-574, 2000.
4. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H and Takeuchi M: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215-221, 2008.
5. Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Takiuchi H, Nasu J, Nakamura K, Fukuda H and Ohtsu A: Randomized phase III study of 5-fluorouracil continuous infusion (5FUci) versus methotrexate and 5-FU sequential therapy (MF) in gastric cancer with peritoneal metastasis (JCOG0106). Proc ASCO 27(Suppl 15): abs. 4545, 2009.
6. Tsukada T, Fushida S, Harada S, Yagi Y, Kinoshita J, Oyama K, Tajima H, Fujita H, Ninomiya I, Fujimura T and Ohta T: The role of human peritoneal mesothelial cells in the fibrosis and progression of gastric cancer. Int J Oncol 41:476-482, 2012.
7. Lv ZD, Na D, Ma XY, Zhao C, Zhao WJ and Xu HM: Human peritoneal mesothelial cell transformation into myofibroblasts in response to TGF-β1 in vitro. Int J Mol Med 27:187-193, 2011.
8. Hay ED: An overview of epithelio-mesenchymal transformation. Acta Anat 154:8-20, 1995.
9. Kalluri R and Neilson EG: Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112:1776-1784, 2003.
10. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442-454, 2002.
11. Nawshad A, Lagamba D, Polad A and Hay ED: Transforming growth factor-beta signaling during epithelial-mesenchymal transformation: implications for embryogenesis and tumor metastasis. Cells Tissues Organs 179:11-23, 2005.
12. Miyazono K, Suzuki H and Imamura T: Regulation of TGF-beta signaling and its roles in progression of tumors. Cancer Sci 94:230-234, 2003.
13. Derynck R and Zhang YE: Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425:577-584, 2003.
14. Dong C, Li Z, Alvarez R Jr and Feng XH and Goldschmidt-Clermont PJ: Microtubule binding to Smads may regulate TGF beta activity. Mol Cell 5:27-34, 2000.
15. Donaldson KL, Goolsby GL, Kiener PA and Wahl AF: Activation of p34cdc2 coincident with taxol-induced apoptosis. Cell Growth Differ 5:1041-1050, 1994.
16. Gelmon K: The taxoids: paclitaxel and docetaxel. Lancet 344:1267-1272, 1994.
17. Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K, Kamei T, Soma D, Miyato H, Yamashita H and Nagawa H: Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol 21:67-70, 2010.
18. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S and Sickel J: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001-1007, 2001.
19. Sakurai Y, Yoshida I, Tonomura S, Sakai W, Nakamura Y, Imazu H, Matsubara T and Ochiai M: Weekly administration of paclitaxel attenuated rectal stenosis caused by multiple peritoneal recurrence 8 years after the resection of gastric carcinoma. Gastric Cancer 6:243-249, 2003.
20. Jordan MA, Toso RJ, Thrower D and Wilson L: Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90:9552-9556, 1993.
21. Axel DI, Kunert W, Göggelmann C, Oberhoff M, Herdeg C, Küttner A, Wild DH, Brehm BR, Riessen R, Köveker G and Karsch KR: Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96:636-645, 1997.
22. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, Dudek D, Fort S, Schiele F, Zmudka K, Guagliumi G and Russell ME; TAXUS II Study Group: Randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 108:788-794, 2003.
23. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ and Russell ME; TAXUS-IV Investigators: A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350:221-231, 2004.
24. Liu X, Zhu S, Wang T, Hummers L, Wigley FM, Goldschmidt-Clermont PJ and Dong C: Paclitaxel modulates TGFbeta signaling in scleroderma skin grafts in immunodeficient mice. PLoS Med 2:1334-1442, 2005.
25. Choi HS, Savard CE, Choi JW, Kuver R and Lee SP: Paclitaxel interrupts TGF-beta1 signaling between gallbladder epithelial cells and myofibroblasts. J Surg Res 141:183-191, 2007.
26. Yung S, Li FK and Chan TM: Peritoneal mesothelial cell culture and biology. Perit Dial Int 26:162-173, 2006.
27. Wakayama T, Sai Y, Ito A, Kato Y, Kurobo M, Murakami Y, Nakashima E, Tsuji A, Kitamura Y and Iseki S: Heterophilic binding of the adhesion molecules poliovirus receptor and immunoglobulin superfamily 4A in the interaction between mouse spermatogenic and Sertoli cells. Biol Reprod 76:1081-1090, 2007.
28. Yagi Y, Fushida S, Harada S, Tsukada T, Kinoshita J, Oyama K, Fujita H, Ninomiya I, Fujimura T, Kayahara M, Kinuya S, Yashiro M, Hirakawa K and Ohta T: Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice. Cancer Chemother Pharmacol 66:745-753, 2010.
29. Yashiro M, Chung YS, Nishimura S, Inoue T and Sowa M: Fibrosis in the peritoneum induced by scirrhous gastric cancer cells may act as 'soil' for peritoneal dissemination. Cancer 77:1668-1675, 1996.
30. Nakazawa K, Yashiro M and Hirakawa K: Keratinocyte growth factor produced by gastric fibroblasts specifically stimulates proliferation of cancer cells from scirrhous gastric carcinoma. Cancer Res 63:8848-8852, 2003.
31. Elenbaas B and Weinberg RA: Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res 264:169-184, 2001.
32. Kinugasa S, Abe S, Tachibana M, Hishikawa Y, Yoshimura H, Monden N, Dhar DK, Nagasue N and Nagaoka S: Over expression of transforming growth factor-beta1 in scirrhous carcinoma of the stomach correlates with decreased survival. Oncology 55:582-587, 1998.
33. Shinto O, Yashiro M, Kawajiri H, Shimizu K, Shimizu T, Miwa A and Hirakawa K: Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells. Br J Cancer 102:844-851, 2010.
34. Yashiro M, Chung YS and Sowa M: Role of orthotopic fibroblasts in the development of scirrhous gastric carcinoma. Jpn J Cancer Res 85:883-886, 1994.
35. Inoue T, Chung YS, Yashiro M, Nishimura S, Hasuma T, Otani S and Sowa M: Transforming growth factor-beta and hepatocyte growth factor produced by gastric fibroblasts stimulate the invasiveness of scirrhous gastric cancer cells. Jpn J Cancer Res 88:152-159, 1997.
36. Koyama T, Yashiro M, Inoue T, Nishimura S, Hirakawa-YS and Chung K: TGF-beta1 secreted by gastric fibroblasts up-regulates CD44 H expression and stimulates the peritoneal metastatic ability of scirrhous gastric cancer cells. Int J Oncol 16:355-362, 2000.
37. Tamura T, Sasaki Y, Nishiwaki Y and Saijo N: Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities. Jpn J Cancer Res 86:1203-1209, 1995.
38. Matsuoka H, Furusawa M, Tomoda H and Seo Y: Difference in cytotoxicity of paclitaxel against neoplastic and normal cells. Anticancer Res 14:163-167, 1994.
39. Gloushankova NA, Lyubimova AV, Tint IS, Feder HH, Vasiliev JM and Gelfand IM: Role of the microtubular system in morphological organization of normal and oncogene-transfected epithelial cells. Proc Natl Acad Sci USA 91:8597-8601, 1994.
40. Schiff PB and Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77:1561-1565, 1980.
41. Zhu S, Goldschmidt-Clermont PJ and Dong C: Transforming growth factor-β-induced inhibition of myogenesis is mediated through Smad pathway and is modulated by microtubule dynamic stability. Circ Res 94:617-625, 2004.
42. Shi Y, Hata A, Lo RS, Massague ÂJ and Pavletich NP: A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature 388:87-93, 1997.
43. Shi Y and Massague J: Mechanisms of TGF-signaling from cell membrane to the nucleus. Cell 113:685-700, 2003.
44. Ten Dijke P, Goumans MJ, Itoh F and Itoh S: Regulation of cell proliferation by Smad proteins. J Cell Physiol 191:1-16, 2002.
45. Liu Q, Mao H, Nie J, Chen W, Yang Q, Dong X and Yu X: Transforming growth factor β1 induces epithelial-mesenchymal transition by activating the JNK-Smad3 pathway in rat peritoneal mesothelial cells. Perit Dial Int 28:S88-S95, 2008.
46. Saika S, Yamanaka O, Ikeda K, Kim-Mitsuyama S, Flanders KC, Yoo J, Roberts AB, Nishikawa-Ishida I, Ohnishi Y, Muragaki Y and Ooshima A: Inhibition of p38MAP kinase suppresses fibrotic reaction of retinal pigment epithelial cells. Lab Invest 85:838-850, 2005.
47. Wendling J, Marchand A, Mauviel A and Verrecchia F: 5-fluorouracil blocks transforming growth factor-beta-induced alpha 2 type I collagen gene (COL1A2) expression in human fibroblasts via c-Jun. NH2-terminal kinase/activator protein-1 activation. Mol Pharmacol 64:707-713, 2003.
48. Zhang D, Sun L, Xian W, Liu F, Ling G, Xiao L, Liu Y, Peng Y, Haruna Y and Kanwar YS: Low-dose paclitaxel ameliorates renal fibrosis in rat UUO model by inhibition of TGF-beta/Smad activity. Lab Invest 90:436-447, 2010.